A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

Sponsor
Janssen-Cilag S.p.A.
Study ID
NCT04439526
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab — DRUG
    Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.

Study Details

The purpose of this study is to investigate the effectiveness profile of guselkumab used in a real-life setting in participants with moderate facial and/or genital psoriasis. Effectiveness will be evaluated using the static Physicians Global Assessment (sPGA) for the facial region and the sPGA for the genital region.

Key Dates

Start date
Jun 10, 2020
Status verified
Jan 2024
Primary completion
Nov 21, 2023
Completion
Nov 21, 2023

Study Design

Enrollment
356 participants (actual)

Arms

  • Arm: Participants with Facial Psoriasis
    Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
  • Arm: Participants with Genital Psoriasis
    Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.

Primary Outcome Measure

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) and at Least a 2-grade Improvement for the Facial Region [ Time Frame: Week 52 ]

Related Studies